Parkinson's disease biomarkers: Perspective from the NINDS Parkinson's Disease Biomarkers Program

Katrina Gwinn, Karen K. David, Christine Swanson-Fischer, Roger Albin, Coryse St Hillaire-Clarke, Beth Anne Sieber, Codrin Lungu, F. Dubois Bowman, Roy N. Alcalay, Debra Babcock, Ted M. Dawson, Richard B. Dewey, Tatiana Foroud, Dwight German, Xuemei Huang, Vlad Petyuk, Judith A. Potashkin, Rachel Saunders-Pullman, Margaret Sutherland, David R. WaltAndrew B. West, Jing Zhang, Alice Chen-Plotkin, Clemens R. Scherzer, David E. Vaillancourt, Liana S. Rosenthal

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.

Original languageEnglish (US)
Pages (from-to)451-473
Number of pages23
JournalBiomarkers in Medicine
Issue number6
StatePublished - Jun 2017

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Parkinson's disease biomarkers: Perspective from the NINDS Parkinson's Disease Biomarkers Program'. Together they form a unique fingerprint.

Cite this